Report Audit™

There is merit in conducting a third party audit of CMS reports prior to attestation and submission to ensure data integrity, completeness and compliance to changing regulations.

The issuance of the OIG Special Fraud Alert and the increasing oversight of the DOJ must prompt Drug and Device Manufacturers to follow stringent measures before submitting their reports to CMS to protect themselves from possible sanctions and to maintain their credibility in the industry.

Hence, similar to a financial audit it is imperative that pharmaceutical compliance teams appreciate and embody the merits of conducting an audit for ensuring transparency.